TY  - JOUR
AU  - Chi, Kim N
AU  - Chowdhury, Simon
AU  - Bjartell, Anders
AU  - Chung, Byung Ha
AU  - Pereira de Santana Gomes, Andrea J
AU  - Given, Robert
AU  - Juárez, Alvaro
AU  - Merseburger, Axel S
AU  - Özgüroğlu, Mustafa
AU  - Uemura, Hirotsugu
AU  - Ye, Dingwei
AU  - Brookman-May, Sabine
AU  - Mundle, Suneel D
AU  - McCarthy, Sharon A
AU  - Larsen, Julie S
AU  - Sun, Weili
AU  - Bevans, Katherine B
AU  - Zhang, Ke
AU  - Bandyopadhyay, Nibedita
AU  - Agarwal, Neeraj
PY  - 2021
DO  - 10.1200/JCO.20.03488
UR  - https://hdl.handle.net/10668/25057
T2  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
AB  - The first interim analysis of the phase III, randomized, placebo-controlled TITAN study showed that apalutamide significantly improved overall survival (OS) and radiographic progression-free survival in patients with metastatic castration-sensitive...
LA  - en
KW  - Androgen Receptor Antagonists
KW  - Disease Progression
KW  - Double-Blind Method
KW  - Humans
KW  - Male
KW  - Neoplasm Metastasis
KW  - Progression-Free Survival
KW  - Prostatic Neoplasms, Castration-Resistant
KW  - Quality of Life
KW  - Thiohydantoins
KW  - Time Factors
TI  - Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.
TY  - research article
VL  - 39
ER  -